KeyBanc raised the firm’s price target on ResMed (RMD) to $298 from $274 and keeps an Overweight rating on the shares. The firm believes ResMed’s Q4 results and initial FY26 commentary largely supported its thesis of sustained mid-to-high-single-digit organic growth, with opportunities for further margin expansion, despite ongoing investor concern around perceived headwinds such as GLP-1s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: